{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=16", "query": { "condition": "Relapse Leukemia", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 1826, "total_pages": 183, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T12:51:18.741Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00357500", "title": "Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Tumor, Pediatric", "Leukemia", "Lymphoma", "Neuroblastoma", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fenofibrate", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 101, "start_date": "2005-01", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-10-01", "last_synced_at": "2026-11-07T12:51:18.741Z", "location_count": 10, "location_summary": "Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 7 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00357500" }, { "nct_id": "NCT03588936", "title": "Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemia", "Chronic Leukemia", "Lymphoma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Nivolumab (.25 mg/kg)", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Nivolumab (.5 mg/kg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2018-09-14", "completion_date": "2020-07-15", "has_results": false, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-11-07T12:51:18.741Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03588936" }, { "nct_id": "NCT00098436", "title": "Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "laromustine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vion Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2004-09", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-11-07T12:51:18.741Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Durham, North Carolina • Cleveland, Ohio", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098436" }, { "nct_id": "NCT06137118", "title": "AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia (B-ALL)" ], "interventions": [ { "name": "Surovatamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 255, "start_date": "2023-12-29", "completion_date": "2028-08-10", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-07T12:51:18.741Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06137118" }, { "nct_id": "NCT00045006", "title": "Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-11-07T12:51:18.741Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045006" }, { "nct_id": "NCT00440726", "title": "Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "PEG-asparaginase", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Triple IT Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 31, "start_date": "2006-08-04", "completion_date": "2011-02-26", "has_results": true, "last_update_posted_date": "2020-02-19", "last_synced_at": "2026-11-07T12:51:18.741Z", "location_count": 20, "location_summary": "Duarte, California • Long Beach, California • Los Angeles, California + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00440726" }, { "nct_id": "NCT01137825", "title": "Registry of Older Patients With Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloproliferative Disorders", "Cognitive/Functional Effects", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [], "intervention_types": [], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 3000, "start_date": "2009-09", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-11-07T12:51:18.741Z", "location_count": 7, "location_summary": "Boone, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina + 4 more", "locations": [ { "city": "Boone", "state": "North Carolina" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Greenville", "state": "North Carolina" }, { "city": "Hendersonville", "state": "North Carolina" }, { "city": "Morehead City", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01137825" }, { "nct_id": "NCT01515176", "title": "Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Prolymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Dinaciclib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2012-01", "completion_date": "2016-07-19", "has_results": true, "last_update_posted_date": "2018-03-15", "last_synced_at": "2026-11-07T12:51:18.741Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01515176" }, { "nct_id": "NCT02258555", "title": "Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "GS-9901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-01", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-10-19", "last_synced_at": "2026-11-07T12:51:18.741Z", "location_count": 6, "location_summary": "Duarte, California • Fresno, California • Whittier, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02258555" }, { "nct_id": "NCT00002778", "title": "Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "1995-02", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2011-07-20", "last_synced_at": "2026-11-07T12:51:18.741Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002778" } ] }